A RESEARCH GUIDE TO FAT LOSS,
APPETITE, AND ENERGY BALANCE

PEPTIDES AND METABOLISM

BY **LUMIN PEPTIDES**

FOR INFORMATIONAL PURPOSES ONLY;
NOT INTENDED AS MEDICAL ADVICE.

LUMIN
PEPTIDES

TABLE OF CONTENTS

INTRODUCTION

What are peptides — and why are researchers so interested in metabolism?

Peptides are **short chains of amino acids** that act as messengers in the body. In research, they're often explored for how they influence key biological systems — from how we grow and recover, to how we store fat and manage energy.

This guide focuses on one of the most active frontiers in peptide science: metabolism. Scientists are investigating how certain peptides may play a role in appetite signaling, fat loss, and energy regulation. Some of these peptides **mimic natural hormones.** Others are synthetic analogs designed to target specific receptors involved in hunger, insulin sensitivity, or fat breakdown.

Whether you're a student, a lab-based researcher, or simply curious about the science behind fat metabolism and peptide signaling, this guide is designed to educate — clearly, ethically, and accessibly.

IMPORTANT REMINDER:

All compounds discussed in this guide are not approved for human use and are offered strictly for research and educational purposes. This is not medical advice, **nor should any content here be interpreted as instruction for personal use**

UNDERSTANDING PEPTIDES & METABOLISM:

A Beginner's Starting Point

WHAT IS METABOLISM?

At its core, metabolism refers to the body's ability to convert food into energy. It includes everything from how we burn calories to how we store fat, balance blood sugar, and manage appetite.

WHY PEPTIDES?

Peptides act like cellular "text messages." They carry very specific instructions — such as "feel full now," "release insulin," or "break down fat." In preclinical settings, researchers explore how these signals might be used to influence energy balance or body composition.

Some peptides are modeled after hormones we already produce, like GLP-1 (a gut hormone that helps you feel full), or GHRH (a growth-hormone-releasing signal that influences fat metabolism).
Others are synthetic fragments, engineered to isolate a specific function — like AOD-9604, which mimics the fat-burning region of growth hormone without the effects on growth itself.



Peptides we'll cover in this guide include:

- **SEMAGLUTIDE, TIRZEPATIDE, AND RETATRUTIDE (GLP-1/GIP AGONISTS)**
- **CAGRILINTIDE (AMYLIN ANALOG)**
- **AOD-9604 (FAT-TARGETING GH FRAGMENT)**
- **TESAMORELIN (GROWTH HORMONE AXIS MODULATOR)**

Each has been explored in early-stage or sponsor-funded trials for its potential role in f**at loss, appetite control, or metabolic improvement** — though none are FDA-approved for these purposes outside of specific clinical indications.

Ready to dive deeper? In the next section, we'll unpack the metabolic system and how peptides may interface with it in research.

THE METABOLIC PUZZLE: HOW PEPTIDES FIT IN

To understand how peptides are explored in metabolic research, it helps to first map out the system they're trying to influence.

Metabolism isn't just about "burning calories" — it's a complex, coordinated network involving **hormones, hunger signals, fat storage, energy use, and glucose regulation.**

KEY PLAYERS IN METABOLIC REGULATION



Hormones like GLP-1, GIP, and amylin tell your brain when you're full. They're central to the body's ability to reduce food intake in response to meals.

The hormone insulin helps cells absorb glucose (sugar) for energy. Some peptides are studied for how they enhance insulin's effect or help regulate blood sugar.



Certain peptides activate pathways related to lipolysis (breaking down fat) or lipogenesis (creating/storing fat).

Some peptides, especially those studied in mitochondrial and GH-axis research, are explored for increasing how many calories the body burns at rest.

WHERE PEPTIDES COME IN

In research, peptides are used as tools to mimic, enhance, or block natural signals.

They may:

- Act like hormones **(e.g., GLP-1 analogs such as Semaglutide)**
- Boost production of native hormones **(e.g., Tesamorelin stimulating GH)**
- Selectively target fat-specific receptors **(e.g., AOD-9604)**

These compounds allow researchers to test **"what happens if we turn this signal up or down?"** in metabolic studies.

WHY THIS MATTERS — AND WHY IT'S COMPLEX

The promise of metabolic peptides is exciting — but it's not simple. **Hunger, fat loss, and energy use are influenced by genetics, hormones, diet, and environment.** Peptides are one piece of the puzzle.
And while many show strong preclinical promise, much more research is needed to understand:

- Long-term effects
- Individual variability
- Safety across populations

That's why this eBook focuses not on promises, but on **explaining the science behind peptide-based metabolic research — clearly and responsibly.**

Next, we'll take a closer look at the GLP-1 pathway and the key gut-derived peptides studied for satiety and blood sugar regulation.

GLP-1S AND GUT-DERIVED PEPTIDE PATHWAYS

Understanding how Semaglutide, Tirzepatide, and Retatrutide are studied for appetite and metabolic control

WHAT IS GLP-1?

GLP-1 stands for glucagon-like peptide-1. It's a hormone released by your intestines when you eat — and it sends signals to your brain and pancreas that help regulate:

- Satiety (feeling full)
- Insulin secretion
- Slower stomach emptying
- Reduced food intake

In short, GLP-1 is one of your body's natural "meal brakes." It helps prevent overeating and improves how your body handles sugar after a meal.

WHY ARE RESEARCHERS STUDYING GLP-1 ANALOGS?

Some peptides are designed to **mimic or enhance GLP-1 signaling in the body.** These analogs are often more stable and longer-lasting than the natural hormone, making them ideal tools in laboratory research.

In preclinical studies, GLP-1 analogs have been shown to:

- Reduce appetite and caloric intake
- Improve glucose control
- Promote body fat reduction

These effects are dose-dependent and vary based on the receptor activity, co-pathway engagement, and metabolic profile of the subject.

BEYOND GLP-1: GIP AND GLUCAGON PATHWAYS

Several next-generation peptides explore multiple receptors beyond GLP-1:

- GIP (Glucose-dependent Insulinotropic Polypeptide):
  Enhances insulin secretion and may support metabolic flexibility
- Glucagon receptor: Stimulates energy expenditure and fat oxidation

Some of the most studied peptides in this space now activate two or even three of these pathways.

PEPTIDES EXPLORED IN RESEARCH

PEPTIDE	TARGETS	RESEARCH INTEREST AREAS
Semaglutide	GLP-1	Satiety, appetite reduction, glucose regulation
Tirzepatide	GLP-1 + GIP	Greater weight loss and glycemic control potential
Retatrutide	GLP-1 + GIP + Glucagon	Energy expenditure, fat oxidation, body composition

These peptides are explored in laboratory settings for how they influence metabolic processes — **and each has its own unique profile, dosing pattern, and mechanism of action.**

We'll break down each one in the next section, along with investigational protocol references.

THE GH AXIS AND BODY COMPOSITION

WHAT IS THE GH AXIS?

The growth hormone (GH) axis is your body's internal messaging system that helps control how you build, repair, and metabolize tissue — especially muscle and fat. Think of it as a three-part communication loop:

1. The hypothalamus (in your brain) releases a signal called GHRH (growth hormone–releasing hormone)
2. The pituitary gland responds by releasing growth hormone (GH)
3. GH then travels to tissues like the liver, muscles, and fat cells, triggering:
    - Fat breakdown (lipolysis)
    - Muscle preservation and growth
    - Release of IGF-1 (insulin-like growth factor-1), which supports energy metabolism and tissue repair

Together, this is known as the GH–IGF-1 axis — a hormonal feedback loop that's central to body composition and metabolic balance.

WHY RESEARCHERS TARGET THE GH AXIS?

This system is a focus in metabolic and aging research because of how precisely it influences body composition:

- **Growth hormone (GH)** encourages the body to burn fat and retain muscle
- **IGF-1, released in response to GH,** supports glucose regulation and cell repair
- Both hormones may impact **insulin sensitivity, visceral fat, and metabolic flexibility (the ability to burn both carbs and fat efficiently)**

By exploring peptides that interface with this axis, researchers aim to better understand how to regulate fat loss, preserve lean mass, and support healthy aging — all without disrupting hormonal balance.

HOW PEPTIDES INTERACT WITH THE GH AXIS

PEPTIDE CLASS	MECHANISM OF ACTION	RESEARCH FOCUS
GHRH analogs (e.g. Tesamorelin)	Mimic brain's GHRH signal to release GH	Reduce visceral fat, boost IGF-1
Ghrelin mimetics (e.g. Ipamorelin, GHRP-2)	Signal GH release through ghrelin pathway	GH support, tissue recovery, hormone tuning
GH fragments (e.g. AOD-9604)	Target fat-burning effects of GH only	Fat metabolism without GH/IGF-1 increase

This is where things get interesting.

Some **GH-related peptides — like Tesamorelin —** are explored for increasing GH and IGF-1 in a controlled, physiologic way. They're studied for how they reduce **visceral fat, especially in settings like HIV-associated lipodystrophy or metabolic syndrome.**

Others — **like AOD-9604 or hGH Fragment 176–191 — are not designed to increase growth hormone at all.** Instead, they mimic only the fat-burning domain of GH, without affecting insulin, blood sugar, or muscle-building pathways.

This selective activity is a major point of interest in fat-targeted metabolic research.



5 FAT-SPECIFIC PEPTIDES

In the next section, we'll take a closer look at these **fat-specific peptides** — including how **AOD-9604** compares to **hGH Fragment 176–191,** and how they've been used in research settings focused on adipose tissue, not systemic growth.

Targeting fat metabolism without systemic growth effects.

WHY TARGETED FAT LOSS IS A UNIQUE RESEARCH GOAL

In many metabolic studies, the goal isn't just to trigger growth hormone — **it's to reduce fat mass in a precise and selective way. That's where fat-specific peptides come in.**

Unlike peptides that raise GH and IGF-1 levels (such as Tesamorelin), fat-targeting compounds are designed **to mimic only the region of GH involved in fat metabolism — without stimulating systemic growth pathways.**

TWO PEPTIDES COMMONLY EXPLORED FOR THIS PURPOSE

PEPTIDE	CLASS	FOCUS IN RESEARCH
AOD-9604	GH Fragment (synthetic)	Selective fat metabolism, lipolysis
hGH Fragment 176–191	GH Fragment (natural sequence	Similar fat-burning region of GH

WHAT MAKES THESE PEPTIDES DIFFERENT?

- Both peptides are derived from the **176–191 fragment** of the **GH molecule**
- They are studied for their ability to stimulate **fat breakdown (lipolysis)**
- Unlike full-length GH, they do not increase **IGF-1** or influence muscle-building hormones

AOD-9604 VS FRAGMENT 176–191: A RESEARCHER'S PERSPECTIVE

AOD-9604 is a stabilized analog of hGH Fragment 176–191.
It's widely used in modern research due to:

- Greater molecular stability
- Minimal interaction with GH or insulin receptors
- More predictable lab handling properties
- This has made **AOD-9604** the dominant fragment used in body composition and fat reduction studies — and the primary focus of Section 6.

STACKING STRATEGIES

In metabolic research, stacking refers to the co-administration of peptides that act on different biological pathways. The goal isn't just to amplify results, but to explore how multiple mechanisms might work together in influencing appetite, fat metabolism, or energy use.

Here are a few commonly referenced research-use-only stacks:

GLP-1 ANALOG + GH FRAGMENT

Example: Semaglutide + AOD-9604

- GLP-1 helps reduce appetite
- AOD-9604 targets fat metabolism directly
- Explored for complementary effects on intake and adipose tissue activity

GLP-1 ANALOG + GH FRAGMENT

Example: Tesamorelin + AOD-9604

- Tesamorelin stimulates the GH/IGF-1 axis
- AOD-9604 acts on fat metabolism independently of GH
- Studied for systemic support + localized fat modulation
- argets fat metabolism directly
- Explored for complementary effects on intake and adipose tissue activity

TRIPLE SATIETY + FAT METABOLISM STACK

Example: Tirzepatide + Cagrilintide + AOD-9604

- GIP/GLP-1 + amylin + GH fragment pathways
- Designed to explore appetite regulation and metabolic balance from multiple hormonal angles

In the next section, we'll explore each individual peptide in detail — including mechanisms, reference protocols, and how they are studied in metabolic and body composition models.

METABOLIC PEPTIDES IN FOCUS

A detailed look at the most studied compounds in fat loss and appetite research.

SEMAGLUTIDE

Overview:

Semaglutide is a GLP-1 receptor agonist studied in metabolic research for its role in regulating satiety, insulin secretion, and calorie intake. It mimics a natural gut hormone that signals fullness after meals.

Mechanism Summary:

- Activates GLP-1 receptors in the brain and gut
- Slows gastric emptying and reduces hunger
- Improves glycemic control in preclinical models

Research Interest Areas:

- Appetite reduction
- Weight regulation
- Blood sugar balance

Investigational Protocol (For Reference Only):

- Start at 0.25 mg SC weekly for 4 weeks
- Escalate to 0.5 mg → 1.0 mg → up to 2.0 mg weekly
- Titration based on published dose-escalation formats in GLP-1 research
- Reconstituted with bacteriostatic water for lab reference

TIRZEPATIDE

Overview:

Tirzepatide is a dual GLP-1 and GIP receptor agonist, explored for its compounded effects on satiety, glucose regulation, and fat loss. It builds on GLP-1 research with added metabolic signaling.

Mechanism Summary:

- Stimulates GLP-1 and GIP receptors
- Enhances insulin sensitivity
- May improve metabolic flexibility and adipose response

Research Interest Areas:

- Fat loss
- Appetite modulation
- Glycemic control

Eli Lilly Protocol Reference (SURPASS-modeled):

- Week 0–4: 2.5 mg SC weekly
- Increase by 2.5 mg every 4 weeks to 15 mg
- Lab studies often run 12–24 weeks
- Reconstitution: sterile water or bacteriostatic saline

RETATRUTIDE

Overview:

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors—explored in emerging research for its ability to accelerate fat loss and potentially preserve lean mass.

Mechanism Summary:

- Increases energy expenditure via glucagon activation
- Enhances satiety through GLP-1 and GIP
- Supports multi-hormonal metabolic control

Research Interest Areas:

- Body fat reduction
- Appetite and energy regulation
- Glucose and lipid metabolism

Investigational Protocol (For Reference Only):

- Start at 2.5 mg SC weekly
- Escalate by 2.5 mg every 4 weeks to 15 mg
- Modeled on advanced incretin agonist designs
- Duration: 12–24 weeks typical in sponsor-linked studies

CAGRILINTIDE

Overview:

Cagrilintide is an amylin receptor agonist studied for its effects on meal size regulation and appetite suppression. It's often co-studied with GLP-1 analogs for potential synergy.

Mechanism Summary:

- Mimics amylin, a hormone that increases satiety
- Delays gastric emptying
- Signals fullness post-meal

Research Interest Areas:

- Appetite suppression
- Caloric intake control
- Combination therapy with GLP-1s

Investigational Protocol (For Reference Only):

- Start at 0.5–1.0 mg SC daily
- Escalate to 1.5–2.0 mg daily over 2–4 weeks
- Often combined with GLP-1 analogs like Semaglutide
- Study durations: 4–12 weeks

AOD-9604

Overview:

AOD-9604 is a modified fragment of the growth hormone molecule (176–191), studied for its ability to selectively target fat metabolism without raising IGF-1 or GH levels.

Mechanism Summary:

- Activates fat-specific pathways in adipose tissue
- Promotes lipolysis
- Avoids systemic growth effects

Research Interest Areas:

- Targeted fat loss
- Body composition modulation
- Non-hormonal metabolic support

Investigational Protocol (For Reference Only):

- Start at 5 mg SC daily
- Optional increase to 10 mg daily after 2–4 weeks
- Typical duration: 4–8 weeks
- Often co-studied with GHRH analogs or GLP-1s

Overview:

Tesamorelin is a synthetic GHRH analog used in studies exploring visceral fat reduction, GH axis modulation, and improvements in IGF-1 signaling.

Mechanism Summary:

- Stimulates the pituitary to release endogenous GH
- Increases IGF-1 in a controlled range
- May support fat metabolism, recovery, and lean mass maintenance

Research Interest Areas:

- Visceral fat reduction
- GH/IGF-1 axis optimization
- Hormonal balance in aging models

Investigational Protocol (For Reference Only):

- Start at 2.0 mg SC daily
- Escalate to 5.0 mg daily after 2 weeks
- Maintain for 8–12 weeks
- Often studied in combination with caloric restriction or other metabolic agents

Compliance Reminder:

All peptides covered in this section are for research use only and are not approved for human consumption. The protocols referenced reflect investigational trial formats and sponsor-based publications. They are provided for educational purposes only.

CHOOSING THE RIGHT PEPTIDE FOR YOUR RESEARCH

How to match your experimental goals with the right metabolic compound:

When planning a peptide-based study, it's helpful to consider your research objective first. What are you aiming to observe or influence?
This section groups peptides based on common focus areas in metabolic research — such as appetite signaling, fat breakdown, or visceral fat reduction. While these categories can overlap, each highlights a distinct biological process.

Reminder:

All peptides listed below are for research use only. These groupings are provided for educational reference and do not reflect therapeutic recommendations.

What this means:

You're studying how peptides influence hunger cues, meal size, or how full an organism feels after eating. This often involves observing food intake or signaling in the brain-gut axis.

Peptides commonly explored:

- **Semaglutide – GLP-1** analog studied for reducing appetite
- **Tirzepatide – Combines GLP-1 and GIP** pathways for enhanced satiety
- **Cagrilintide – Amylin** analog that may help regulate meal frequency or size
- **Retatrutide –** Adds glucagon receptor engagement to appetite control

What this means:

Your study focuses on how peptides may affect stored body fat — particularly subcutaneous adipose tissue — and whether they influence fat mobilization or usage for energy.

Peptides commonly explored:

- AOD-9604 – GH fragment analog studied for direct lipolytic activity
- hGH Fragment 176–191 – Less stable version of the same GH region
- Retatrutide – Triple agonist that may enhance fat oxidation via glucagon action



What this means:

You're targeting deeper fat stores — especially around internal organs — or looking to influence the GH–IGF-1 hormonal system involved in metabolism, recovery, and body composition.

Peptides commonly explored:

- Tesamorelin – GHRH analog studied for reducing abdominal fat and raising IGF-1
- Tirzepatide – Also shows potential in reducing waist circumference in early studies
- CJC-1295 + Ipamorelin – Explored in GH stimulation protocols for lean mass preservation (covered in performance eBook)

MULTI-PATHWAY OR STACKED DESIGNS

What this means:

You're combining peptides to study synergistic or complementary effects — such as pairing appetite control with fat-burning signals, or modulating central and peripheral pathways together.

Examples of research-use-only stacks:

- Semaglutide + AOD-9604 – Satiety + fat metabolism targeting
- Tesamorelin + AOD-9604 – GH axis support + localized fat breakdown
- Tirzepatide + Cagrilintide – Dual satiety and gastric regulation
- Retatrutide + AOD-9604 – Multi-hormonal signaling + lipolytic support

FINAL NOTE:

These groupings are not rigid. Many researchers tailor protocols based on specific study endpoints — such as fat distribution, caloric intake, hormone levels, or inflammatory markers.

Always align compound selection with your intended research outcome.

LAB HANDLING & RECONSTITUTION TIPS

Choosing the Right Peptide for Your Research

Most peptides arrive as a **lyophilized (freeze-dried) powder,** which must be reconstituted before use in the lab. This section walks through sterile prep techniques, storage guidance, and links to tools like Lumin's Dosage Calculator to support research professionals.

All guidance below is for educational reference in laboratory environments. These compounds are not approved for human use.

STEP 1 SELECT A DILUENT

Use bacteriostatic water (BSW) unless your study protocol calls for something else. It contains a small amount of benzyl alcohol to inhibit contamination and is widely used in peptide research.

Other diluents occasionally used:

- Sterile water – less shelf-stable, suited for immediate use
- 0.6% Acetic acid – helpful for acidic peptides (e.g., DSIP, MOTS-c)
- Normal saline – used selectively for isotonicity

Lumin's Reconstitution Kit includes BSW, syringes, alcohol pads, and sterile prep tools — available as an optional add-on.

STEP 2 RECONSTITUTE THE PEPTIDE

Instructions:

- Wipe all vial tops with an alcohol swab
- Use a sterile syringe to draw up your chosen diluent
- Insert the needle into the vial and slowly inject down the glass wall
- Allow powder to dissolve — swirl gently, never shake
- Label vial with peptide name and reconstitution date

Example:

- 5 mg peptide + 1 mL BSW → 5 mg/mL (or 5000 mcg/mL)
- Adjust dilution to match your desired concentration or protocol volume

STEP 3 STORAGE & STABILITY

Once reconstituted:

- Refrigerate at 2–8°C (36–46°F)
- Use within 4–6 weeks, depending on peptide stability
- Avoid light exposure; store in amber vials or keep boxed
- Do not freeze unless specified for long-term storage

Peptide-specific notes:

- GHK-Cu – Sensitive to oxidation; minimize air exposure
- MOTS-c, SS-31 – Less stable post-reconstitution; best used within 2–3 weeks
- AOD-9604, GLP-1s – Typically stable for 4–6 weeks under sterile refrigeration

Consider aliquoting peptides into smaller sterile vials to reduce exposure from repeated handling.

COMMON HANDLING CAUTIONS

- Do not shake vials — it can degrade fragile peptide bonds
- Always use a clean syringe and needle; never reuse
- Do not touch vial stoppers after cleaning
- Ensure a clean, sterile surface and avoid open-air exposure
- Label all vials clearly with contents and reconstitution date

USE THE LUMIN PEPTIDES DOSAGE CALCULATOR

To simplify your prep, use the Lumin Dosage Calculator — a free online tool built for research planning.

You can input:

- Total vial dosage (e.g., 5mg, 10mg)
- Desired dilution volume (e.g., 1mL, 2mL)
- Target dose per use (e.g., 250 mcg)

It calculates:

- Final concentration
- Volume per dose
- Number of doses per vial

You'll find the calculator linked on every Lumin peptide product page and the main Tools section.

Peptide Lab Prep Essentials:

- Alcohol swabs
- Bacteriostatic water
- Sterile syringe & needle
- Clean work surface
- Labeled vial
- Correct dilution volume
- Refrigerated storage
- Lumin Calculator (for dose planning)

Summary & Key Takeaways:

What we've learned about metabolic peptides in research:

Peptides are rapidly becoming some of the most studied tools in metabolic research — not because they promise shortcuts, but because they offer **precise control over signaling systems involved in fat loss, appetite, and energy regulation**.

This guide has covered:

- The basics of metabolic function and how peptides fit into that system
- A deep dive into **GLP-1, GIP, amylin, and GH pathways**
- Specific peptide profiles like **Semaglutide, Tirzepatide, AOD-9604, and Tesamorelin**
- Research protocols, titration patterns, and stacking strategies
- Practical lab prep guidance and reconstitution best practices

KEY PRINCIPLES TO REMEMBER

- **Match your peptide to your research goal**

Whether you're studying satiety, fat metabolism, or hormonal modulation, each peptide serves a different function.

- **Peptides are not interchangeable**

A GLP-1 analog like Semaglutide does not behave like a **GH fragment.** Know the mechanisms.

- **Dose escalation matters**

Titration helps reduce variables and mimics sponsor-modeled studies — especially for compounds like **Tirzepatide and Tesamorelin.**

- **Stacking is strategic, not default**

Only combine peptides when there's a clear scientific rationale, such as dual pathway exploration **(e.g., satiety + lipolysis).**

- **Sterile prep protects your study**

Clean technique, proper storage, and accurate dilution all preserve peptide integrity and data quality.

FINAL DISCLAIMER

- All peptides discussed in this guide are not approved for human use and are provided f**or research and education only.** None of this content is intended to diagnose, treat, or recommend personal protocols. Always conduct your work in alignment with **institutional and regulatory guidelines.**

- If you'd like to explore peptide research in performance, recovery, or neurocognitive support, check out the rest of the **Lumin eBook library — each one is tailored to a different biological domain.**

REFERENCES

Select scientific sources and study models referenced in this guide

- Frias, J. P., et al. (2021). Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-2). New England Journal of Medicine, 385, 503–515.

→ DOI: 10.1056/NEJMoa2107519

(Reference for Tirzepatide protocol and dual receptor action)

- Overgaard, R. V., et al. (2021). Pharmacokinetics and dose modeling of semaglutide for once-weekly administration. Diabetes, Obesity and Metabolism, 23(3), 672–680.

→ DOI: 10.1111/dom.14290

(Reference for Semaglutide dose escalation and GLP-1 receptor agonism)

- Le Roux, C. W., et al. (2023). Retatrutide phase 2 trial for obesity and metabolic health. New England Journal of Medicine, 389, 203–214.

→ DOI: 10.1056/NEJMoa2301972

(Reference for Retatrutide as triple agonist and titration logic)

- Heymsfield, S. B., et al. (2009). Amylin analogs and the physiology of satiety: Mechanisms of Cagrilintide. International Journal of Obesity, 33(4), 405–415.

→ DOI: 10.1038/ijo.2009.2

(Reference for Cagrilintide and amylin pathway)

- Ng, F. M., et al. (2000). AOD-9604, a novel fragment of human growth hormone, promotes lipolysis without IGF-1 elevation. European Journal of Pharmacology, 408(2), 185–193.

→ DOI: 10.1016/S0014-2999(00)00703-3

(Primary preclinical reference for AOD-9604's selective fat metabolism action)

- Grunfeld, C., et al. (2007). Tesamorelin and visceral adipose tissue in HIV-associated lipodystrophy. Journal of Clinical Endocrinology & Metabolism, 92(3), 1081–1088.

→ DOI: 10.1210/jc.2006-1692

(Reference for Tesamorelin GH axis mechanism and visceral fat research)

- Peptide stability and handling guide. Sigma-Aldrich Technical Bulletin: Peptide Handling and Storage.

→ Sigma-Aldrich Peptide Handling

(General reference for peptide reconstitution, storage, and stability practices)